Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $4.4152W HIGH $12.70
Volume
63.78 K
Value Traded
435.08 K
Short % Float
5.75%
Days to Cover
4.4
+6.67%Week
-30.5%1 Month
+23.58%3 Month
+13.25%6 Month
-72.38%5 Year
-97.53%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
67.80 M
EPS (TTM)
-1.64
P/E Ratio
-
Ent. Value
66.52 M
Total Shares
9.01 M
Float Shares
6.05 M
Insiders
32.89%
Institutions
13.67%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
ECOR Catalyst Timeline
Dated clinical, regulatory and corporate events for electroCore, Inc.
Past FDA Catalysts and PDUFA Decisions
How ECOR actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 97%
Micro Cap(rank 637 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every ECOR program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Errico Thomas J.Director | Buy | 5,000 363,904 held | $9.82 | 09/14/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ECOR
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in ECOR for Q2 2026. | ||||
ECOR Institutional Ownership Trends
ECOR Short Interest
Shares sold short, counted twice a month.
5.75%
Short % of Float
of tradable shares sold short
347.7K
Shares Sold Short
+10.6% vs prior count
4.4 Moderate
Days to Cover
trading days of normal volume to buy every short share back
79.0K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ECOR ranks across every disease it competes in
Competitive Position is a premium feature
See how ECOR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialECOR News
ECOR▼ -3.1%today
electroCore to Announce Third Quarter September 30, 2026, Financial Results on Wednesday, November 4, 2026
electroCore, Inc. will announce its third-quarter financial results for 2026 on November 4. The results will be shared after market close, followed by a conference call at 4:30 PM EST. This event will allow management to review the results and address any investor questions.
Read more →ECOR▲ +8.5%on this newsshared move
electroCore, Inc. Submits 510(k) Premarket Notification to FDA Seeking Clearance of Quell® for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy (CIPN)
electroCore, Inc. has submitted a 510(k) premarket notification to the FDA for its Quell® device aimed at treating chronic chemotherapy-induced peripheral neuropathy (CIPN). The submission is backed by clinical evidence from two studies involving 168 subjects, showing significant improvements in pain and quality of life. If cleared, Quell would be one of the first devices specifically indicated for CIPN.
Read more →ECORelectroCore to Present at Planet MicroCap Toronto 2026 powered by MicroCapClub
electroCore, Inc. announced its participation in the Planet MicroCap Toronto 2026 conference. Co-CEO Joshua Lev will present on October 28 and conduct one-on-one investor meetings. The event will take place at the Arcadian Court & Loft in Toronto from October 27-29. The company specializes in non-invasive bioelectronic technologies for health improvement.
Read more →ECORelectroCore to Participate at H.C. Wainwright Global Investment Conference
electroCore, Inc. will participate in the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026. Co-CEO Joshua Lev will engage in a fireside chat and hold one-on-one meetings with investors. This event highlights the company's focus on bioelectronic medicine and its innovative products aimed at improving health and wellness.
Read more →ECORelectroCore, Inc. Appoints Joshua Lev and Mike Fox as Co-Chief Executive Officers
electroCore, Inc. has appointed Joshua Lev and Mike Fox as Co-Chief Executive Officers, effective September 8, 2026. This decision follows a thorough leadership process, recognizing both leaders' complementary strengths. They aim to enhance the company's strategy and performance while focusing on revenue growth and innovation in bioelectronic technologies.
Read more →ECORelectroCore’s Truvaga® Named Best Luxury Biohacking & Longevity Brand in the USA by Luxury Lifestyle Awards
electroCore's Truvaga has been awarded the title of Best Luxury Biohacking & Longevity Brand in the USA by Luxury Lifestyle Awards. This recognition highlights Truvaga's innovative approach to wellness through non-invasive vagus nerve stimulation technology, designed to enhance relaxation and overall wellbeing. The brand emphasizes a high-touch customer experience, making nervous system wellness accessible for everyday use.
Read more →ECOR▲ +20.7%on this news· ran to +40% by day 3
electroCore Announces Second Quarter 2026 Financial Results
electroCore, Inc. reported a 28% increase in net sales for Q2 2026, reaching $9.5 million. The company also improved its adjusted EBITDA net loss by 26% year-over-year. With significant changes in its commercial organization, electroCore is optimistic about achieving over 30% revenue growth for the full year 2026 and aims for positive adjusted EBITDA by Q3 2027.
Read more →ECORelectroCore to Participate in Upcoming Investor Conferences
electroCore, Inc. announced its participation in two upcoming investor conferences, including the Needham 11th Annual Virtual MedTech and Diagnostics Conference and the Canaccord Genuity 46th Annual Growth Conference. Management will host presentations and one-on-one meetings to engage with investors. This participation highlights the company's focus on investor relations and its innovative bioelectronic technologies.
Read more →ECORelectroCore to Announce Second Quarter June 30, 2026, Financial Results on Thursday, August 6, 2026
electroCore, Inc. announced that it will report its financial results for the second quarter ending June 30, 2026, on August 6, 2026. The company will host a webinar at 4:30 PM EDT to discuss these results and address investor questions. electroCore focuses on bioelectronic technologies aimed at improving health and quality of life.
Read more →ECORNew Review Examines Anatomical and Methodological Differences Between Auricular and Cervical Vagus Nerve Stimulation
electroCore, Inc. has published a peer-reviewed review article comparing auricular and cervical vagus nerve stimulation methods. The article discusses their anatomical differences, mechanisms of action, and clinical evidence. It emphasizes the growing support for cervical vagus nerve stimulation as a validated approach and outlines future research opportunities in the field of bioelectronic medicine.
Read more →ECORelectroCore to Participate in iAccess Alpha Virtual Best Ideas Summer Investment Conference
electroCore, Inc. will participate in the iAccess Alpha Virtual Best Ideas Summer Investment Conference on June 23-24, 2026. The company's Interim President and CFO, Joshua Lev, will present and conduct one-on-one meetings with investors. This event highlights electroCore's commitment to engaging with investors and promoting its bioelectronic health technologies.
Read more →ECORFrontiers in Neuroscience Accepts Review Article Synthesizing Evidence that Cervical nVNS Activates the Vagus Nerve Without Surgery
electroCore, Inc. announced that a review article on cervical non-invasive vagus nerve stimulation (nVNS) has been accepted for publication in Frontiers in Neuroscience. Authored by a team of experts, the article consolidates evidence supporting the effectiveness of nVNS in activating vagal pathways without surgery. This publication aims to address skepticism regarding non-invasive vagal activation and reinforces the clinical validation of cervical nVNS.
Read more →ECOR▼ -8.7%on this news
electroCore to Present at the Planet MicroCap Las Vegas 2026 Powered by MicroCapClub
electroCore, Inc. will present at the Planet MicroCap Las Vegas 2026 event, scheduled for June 17-18, 2026. Interim President and CFO Joshua Lev will lead the presentation and conduct one-on-one investor meetings. The event aims to connect public companies with investors, highlighting electroCore's advancements in bioelectronic medicine.
Read more →ECOR▼ -5.6%on this news
electroCore Announces Publication in JAMA Highlighting the Benefits of Adding Quell Electrical Nerve Stimulation to Outpatient Physical Therapy in Fibromyalgia
electroCore, Inc. announced the publication of a study in JAMA Network Open, demonstrating the effectiveness of the Quell device in reducing pain for fibromyalgia patients undergoing outpatient physical therapy. The study involved 384 participants and showed significant improvements in pain and fatigue levels. The results indicate that Quell may serve as a beneficial non-drug treatment option for fibromyalgia.
Read more →ECORelectroCore to Present at the LD Micro Invitational XVI Conference on May 18, 2026
electroCore, Inc. will present at the LD Micro Invitational XVI Conference on May 18, 2026. The event will take place at the Luxe Sunset Boulevard hotel in Los Angeles, where Interim President and CFO Joshua Lev will deliver a presentation and conduct one-on-one meetings. This engagement highlights the company's focus on bioelectronic medicine and wellness.
Read more →ECORelectroCore Announces First Quarter 2026 Financial Results
electroCore, Inc. announced its financial results for Q1 2026, reporting net sales of $9.6 million, a 43% increase compared to the previous year. The company experienced a net loss of $5.3 million, which includes costs related to leadership transitions. Despite these challenges, gross profit margins improved to 87%, highlighting operational advancements. The company reaffirmed its full-year 2026 revenue growth guidance of approximately 30% over 2025, driven by ongoing sales increases in their prescription and wellness product lines.
Read more →ECOR▲ +5.9%on this news
electroCore TAC-STIM™ Named National Semifinalist in National Safety Council Work to Zero Challenge
electroCore, Inc. announced that its TAC-STIM product has been named a national semifinalist in the 2026 Work to Zero Safety Innovation Challenge. This initiative by the National Safety Council aims to identify technologies that can mitigate workplace fatigue, a significant safety risk. TAC-STIM is designed to enhance decision-making and performance in high-demand environments, particularly for military personnel.
Read more →ECORelectroCore to Announce First Quarter March 31, 2026, Financial Results on Wednesday, May 6, 2026
electroCore, Inc. will report its financial results for Q1 2026 on May 6, 2026. A webinar will be held at 4:30 PM EDT for management to discuss the results and answer investor questions. The company specializes in bioelectronic medicine, focusing on non-invasive technologies for chronic pain and wellness.
Read more →ECORelectroCore to Present at the Market Movers Investor Summit on May 5, 2026
electroCore, Inc. will participate in the Market Movers Investor Summit on May 5, 2026, at the historic Bank of New York. Interim President and CFO Joshua Lev will present and conduct one-on-one meetings. The summit aims to connect company executives with investors, featuring various presentations and networking opportunities.
Read more →ECORelectroCore Product Line Featured in Documentary Underscoring the Expanding Clinical and Commercial Role of Vagus Nerve Stimulation
electroCore, Inc. announced its participation in the documentary 'Hacking the Vagus Nerve,' which explores the vagus nerve's role in health. The film features electroCore's technologies, including gammaCore for migraines and Truvaga Plus for stress management. As interest in vagus nerve stimulation grows, electroCore aims to advance its therapeutic applications.
Read more →About electroCore, Inc.
Headquarters200 FORGE WAY, ROCKAWAY, NJ, 07866
BIOPHARMAWATCH ELITE PLUS
Trade the next ECOR catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime